secwatch.observer — SEC 8-K summary
======================================

Issuer:     Outlook Therapeutics, Inc. (OTLK)
CIK:        0001649989
Form:       8-K
Filed at:   2025-06-02T23:59:59+00:00
Accession:  0001104659-25-055521
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Outlook Therapeutics launches LYTENAVA (bevacizumab gamma) in Germany and UK for wet AMD
--------------------------------------------------------------------------------

- Commercial launch of LYTENAVA (bevacizumab gamma) in Germany and UK announced on June 2, 2025.
- Indication: treatment of wet age-related macular degeneration (wet AMD).
- First approved bevacizumab gamma product for wet AMD in these two markets.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1649989/000110465925055521/0001104659-25-055521-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1649989/000110465925055521/tm2516951d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-055521

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer